TMS Co., Ltd Logo

TMS Co., Ltd

Develops small molecule drugs from natural compounds for the global pharmaceutical market.

4891 | T

Overview

Corporate Details

ISIN(s):
JP3544960002
LEI:
Country:
Japan
Address:
府中市府中町一丁目9番地京王府中1丁目ビル11階
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TMS Co., Ltd. is a biotechnology company engaged in the research, development, manufacture, and sale of pharmaceuticals, quasi-drugs, drug substances, and medical devices. The company focuses on developing small molecule drug candidates derived from natural compound libraries, collaborating with academic institutions to bridge scientific discoveries with the global pharmaceutical market. Its research includes the development of SMTPs (Small Molecule Therapeutic Products), which have shown potential in promoting thrombolysis, suppressing inflammation, and providing antioxidation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-15 08:41
Report Publication Announcement
確認書
Japanese 7.9 KB
2025-10-15 08:40
Interim Report
半期報告書-第22期(2025/03/01-2025/12/31)
Japanese 212.5 KB
2025-05-30 03:20
Post-Annual General Meeting Information
臨時報告書
Japanese 27.5 KB
2025-05-30 03:18
Registration Form
確認書
Japanese 7.9 KB
2025-05-30 03:17
Governance Information
内部統制報告書-第21期(2024/03/01-2025/02/28)
Japanese 21.1 KB
2025-05-30 03:15
Annual Report
有価証券報告書-第21期(2024/03/01-2025/02/28)
Japanese 2.9 MB
2025-04-09 09:05
Regulatory News Service
臨時報告書
Japanese 19.9 KB
2025-03-14 07:58
Registration Form
有価証券届出書(組込方式)
Japanese 407.4 KB
2025-02-28 07:37
Legal Proceedings Report
臨時報告書
Japanese 18.5 KB
2025-02-06 09:01
Regulatory News Service
臨時報告書
Japanese 19.1 KB
2024-10-15 08:18
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-10-15 08:15
Interim Report
半期報告書-第21期(2024/03/01-2025/02/28)
Japanese 176.1 KB
2024-07-12 08:14
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-07-12 08:12
Quarterly Report
四半期報告書-第21期第1四半期(2024/03/01-2024/05/31)
Japanese 125.8 KB
2024-05-29 03:27
Registration Form
確認書
Japanese 7.9 KB

Automate Your Workflow. Get a real-time feed of all TMS Co., Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TMS Co., Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TMS Co., Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

kainos loboratories,inc Logo
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan
4556
Kairos Pharma, LTD. Logo
Develops novel oncology therapies to reverse drug resistance and immune suppression.
United States of America
KAPA
KAKEN PHARMACEUTIAL CO., LTD. Logo
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan
4521
KALA BIO, Inc. Logo
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America
KALA
Kalaris Therapeutics, Inc. Logo
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America
KLRS
KalVista Pharmaceuticals, Inc. Logo
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America
KALV
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel
KMDA
KAMADA LTD Logo
Develops specialty plasma-derived therapeutics for rare and serious diseases.
United States of America
KMDA
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom
KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden
KAN

Talk to a Data Expert

Have a question? We'll get back to you promptly.